Clinical Trials Browser

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Phase 3 Active not recruiting

454 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

1,902 enrolled

Breast

Breast Neoplasms

NCT04498117 2026-04-01

FLORA-5

Phase 3 Active not recruiting

615 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05605535 2026-04-01

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Phase 2 Active not recruiting

88 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04205812 2026-03-31

POD1UM-304

Phase 3 Active not recruiting

583 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03473743 2026-03-30

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Phase 1/2 Active not recruiting

125 enrolled 19 charts

Genitourinary

Carcinoma, Transitional Cell

NCT04129502 2026-03-30

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Phase 3 Active not recruiting

354 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04736173 2026-03-30

ARC-10

Phase 2 Active not recruiting

169 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05815160 2026-03-30

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Phase 1 Active not recruiting

34 enrolled

Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT06008093 2026-03-30

TRITON

Phase 2 Active not recruiting

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05017012 2026-03-27

MK-3475A-C18

Phase 1 Active not recruiting

72 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05555732 2026-03-25

TROPION-Lung07

Phase 3 Active not recruiting

1,170 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05771480 2026-03-25

TOURMALINE

Phase 3 Active not recruiting

142 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT06396065 2026-03-24

Phase III Study of AK112 for NSCLC Patients

Phase 3 Active not recruiting

420 enrolled

Thoracic

Non-Squamous Non-small Cell Lung Cancer

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Active not recruiting

453 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06726265 2026-03-18

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Phase 3 Active not recruiting

756 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05142696 2026-03-17

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Phase 1/2 Active not recruiting

24 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer

NCT05984277 2026-03-17

eVOLVE-Lung02

Phase 3 Active not recruiting

1,200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Thoracic

Non Small Cell Lung Cancer NSCLC

NCT05687266 2026-03-13

AVANZAR

Phase 3 Active not recruiting

1,350 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Phase 1 Active not recruiting

750 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06704724 2026-03-13